Correction of ADC Plant Investment: Amount Increased to KRW 96 Billion
-
Investment amount corrected: from KRW 85.46B to KRW 96B (+KRW 10.54B, +12.3%)
-
Ratio to equity: 59.19% → 66.49%
-
Purpose: Build GMP production facility for ADC CDMO business
-
Period: 2024-08-14 to 2026-12-31
-
Reason for increase: Productivity improvement via facility expansion and design changes
-
Location: Asan, Chungcheongnam-do
KOSPI Filing Information
-
Filing: [Correction of Description] Investment in New Facilities, etc.
-
Company: Kyongbo Pharmaceutical (214390)
-
Submission: Kyongbo Pharmaceutical Co., Ltd.
-
Receipt: 02-02-2026
-
Under KRX KOSPI Market Division